Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

December 25, 2022

Study Completion Date

December 31, 2025

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

CCRT+GP

Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.

DRUG

CCRT+PF

Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.

Trial Locations (4)

410000

The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha

510000

Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

550000

The Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang

All Listed Sponsors
lead

Sun Yat-sen University

OTHER